Coatings

Our customized medical coatings deliver superior infection control, therapeutic delivery, and increased lubricity. Using our CovaCoat™ technology platform, we collaborate with customers to develop custom and proprietary medical device coatings that offer strategic marketing advantages for their product offerings. CovaCoat™ technology provides a cost-effective and proprietary photochemical process for covalently linking coating molecules to a variety of medical device surfaces for exceptional functionality and performance. Specific coating formulations signal passive or active healing responses to the device.

Brochure Download

CovaCoat™ may be customized to provide medical devices specific properties:

  • Lubricious
  • Hemocompatible
  • Antithrombogenic
  • Biocompatible
  • Antimicrobial
  • Controlled drug delivery
  • ID/OD coating

Virtually any medical device or other surface material can be coated with our CovaCoat technology. Each formulation can be engineered to provide controlled delivery of various therapeutics. 

The CovaCoat process features sophisticated controls built into the coating process that provides for batch size flexibility or continuous flow production to ensure consistent outcomes. All process applications developed with ISO compliant quality systems are scaled‐up at Covalon prior to technology transfer. Medical companies can choose to apply the coatings in‐house or through a contract manufacturer.

CovaCoat™ Features and Benefits:

DURABLE

Covalently linked surface coating withstands very high shearing and abrasion forces

PATENTED

Provides product differentiation

CUSTOMIZABLE

For varying geometries, devices and materials

FLEXIBLE

Controlled delivery of antimicrobials, antibiotics, peptides and anti‐proliferates

COST EFFECTIVE

Costs are spread across numerous applications

BULK PROPERTIES FRIENDLY

Devices perform as intended with improved features

SCALABLE

All process applications are scaled‐up prior to technology transfer

COMMERCIALLY PROVEN

Multiple applications in market with clinical validation